Updated news of the industry
A paper written by Brazilian researchers in Brazil disclosed detailed late-stage test data of the Covid-19 vaccine developed by Sinovac, which may help alleviate concerns about such domestic information due to the lack of such public information will exacerbate this concern.
The preprint has not yet been peer-reviewed and was released on Sunday through the online research platform SSRN. It said that Sinovac's inactivated virus vaccine, called CoronaVac, is 50.7% effective in preventing symptomatic Covid-19 cases. The figure previously given by Brazilian officials was 50.4%.
Researchers found that the effective rates for "assisted" cases and cases with moderate to severe symptoms were 83.7% and 100%, respectively.
The paper stated that a total of 12,396 volunteers participated in the third phase of the clinical trial, which was conducted in 16 locations in Brazil from July to December last year. Volunteers must be health care professionals caring for Covid-19 patients.
A total of 67 serious adverse events were detected among the 64 participants who received two CoronaVac doses (including two deaths). The study said that these events were "determined as not related to the vaccine."
CoronaVac is one of the four domestic Covid lenses approved by China. It has also been approved by more than a dozen other countries, including Indonesia, Brazil, Turkey and Malaysia. However, due to lack of transparency, shooting has also been questioned.
The release of this study marks the first public release of the results of the Chinese vaccine's late-stage trial, because so far, only the early and mid-term trial results of the Chinese vaccine have been published. These trials are not designed to check whether the vaccine actually prevents people from getting sick from the disease, although many officials and managers have announced total efficacy figures.
As China has effectively controlled the epidemic, the country’s vaccine companies are forced to find countries with uncontrolled spread to test their vaccines. This is sometimes politically stressful.
CoronaVac is one of the main vaccines currently used for vaccination in Brazil, which is one of the countries with the most severe Covid-19 pandemic. According to data compiled by Johns Hopkins University, as of Tuesday, the country has reported more than 13.5 million coronavirus cases and more than 2.9 million deaths. The government’s goal is to vaccinate 51 million people in the first half of this year, about a quarter of the total population.